Correlation Between Karyopharm Therapeutics and Erasca

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Erasca at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Erasca into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Erasca Inc, you can compare the effects of market volatilities on Karyopharm Therapeutics and Erasca and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Erasca. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Erasca.

Diversification Opportunities for Karyopharm Therapeutics and Erasca

0.34

Correlation Coefficient

Karyopharm Therapeutics  Erasca

Weak diversification

The 3 months correlation between Karyopharm and Erasca is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Erasca Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Erasca Inc and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Erasca. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Erasca Inc has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Erasca go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Erasca

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Erasca. In addition to that, Karyopharm Therapeutics is 1.3 times more volatile than Erasca Inc. It trades about -0.03 of its total potential returns per unit of risk. Erasca Inc is currently generating about 0.0 per unit of volatility. If you would invest  411.00  in Erasca Inc on September 26, 2024 and sell it today you would lose (154.00) from holding Erasca Inc or give up 37.47% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	99.8%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Erasca Inc

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Erasca Inc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Erasca Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Erasca is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Karyopharm Therapeutics and Erasca

The main advantage of trading using opposite Karyopharm Therapeutics and Erasca positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Erasca can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erasca will offset losses from the drop in Erasca's long position.

The idea behind Karyopharm Therapeutics and Erasca Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.